October 26, 2017

ADC Therapeutics Raises $200M to Fund Two Lead Programs in Non-Hodgkin’s Lymphoma

News

ADC Therapeutics, a company specializing in the development of antibody drug conjugates (ADCs) for several cancer indications, has raised $200 million through a private placement. The financing will be used ... Read more

June 26, 2017June 26, 2017

ADC Reports Positive Phase 1 Results on Antibody-drug Conjugate ADCT-301 for Hodgkin’s, NHL

News

Preliminary results from a Phase 1 trial testing ADC Therapeutics’ ADCT-301 to treat relapsed or refractory Hodgkin’s and non-Hodgkin’s lymphoma (NHL) demonstrated the medication’s therapeutic potential with good overall response rates and low ... Read more